Archive


Category: cardiovascular

  • TargED Bio raises €39m for new clot-busting drug

    There’s been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and stroke for decades, but a small Dutch biotech – TargED Biopharmaceuticals – is hoping to disrupt the market with a new and improved therapy. It has just raised €39 million ($44 million) in first-round financing to help […]

  • Pfizer sees no way forward for Ionis-partnered vupanorsen

    Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase 2b data raised some questions about the antisense drug’s efficacy and safety. It’s a setback to Pfizer’s late-stage pipeline, given that at one point the company was projecting $3 billion in potential sales for vupanorsen, which targets […]

  • Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

    Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed it met its main efficacy targets, but raised a few safety concerns as well. The top-line results of the TRANSLATE-TIMI 70 study – in dyslipidaemia patients with elevated non-HDL cholesterol and triglycerides – showed that vupanorsen was […]

  • AZ, Moderna say mRNA drug is promising in heart failure

    Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart failure. At the American Heart Association (AHA) congress, the two partners presented results from the phase 2a EPICCURE trial that showed that injecting their AZD8601 […]

  • Smartphone-powered trial backs J&J’s Invokana for heart failure

    Johnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms in a clinical trial that relied entirely on remote monitoring of symptoms using a smartphone app. The real-world CHIEF-HF study is said to be the first fully “decentralised, mobile, indication-seeking clinical study” with no need for patients […]

  • Artery Heart Disease is Different in Women

    Artery Heart Disease is Different in Women There is no better example of the disconnect between what we know and what we do than in the case of women with heart artery disease. The Doctor Weighs In

  • How Antiarrhythmic Drugs are Used in Cardiac Life Support

    One of the most interesting types of cardiovascular pharmaceuticals around is antiarrhythmic drugs, which can change the way your heartbeats. Antiarrhythmic drugs help counteract abnormal heart rhythms resulting from the irregular electrical activity. These could include atrial fibrillation, atrial flutter, supraventricular tachycardia, and Wolff-Parkinson-White syndrome, among others. When used, the goal of these medications is […]